Effect of Jintiange capsule on acute bone atrophy resulting from wrist fractures: A randomized controlled trial

Objective: To investigate the efficacy of Jintiange capsule in the treatment of acute bone atrophy due to wrist fractures. Methods: Participants were randomly allocated into two groups, i.e. the treatment group and the control groups. All patients received functional rehabilitation exercise. Patients in the treatment group received Jintiange capsule orally, while the control group received placebos. At 3 and 6 months after the treatment, Cooney score, hand grip and pinch strength were measured. The visual analogue scale (VAS) was applied, and safety events were recorded. Results: No loss occurred during 6 months of follow-up after treatment. Before the treatment, there was no statistically significant difference between the two groups in Cooney score, hand grip strength, hand pinch strength or VAS score (all P>0.05). At 3 and 6 months after the treatment, the Cooney core, hand grip and pinch strength increased, and the VAS were decreased in all patients. The treatment group showed significantly greater improvement than the control group (P<0.05). In additional, both groups showed few side effects. Conclusions: Jintiange capsule can improve the function of the wrist joint and alleviate the pain of fracture. It is safe and effective for treating acute bone atrophy.

Transcriptome sequencing-based study on the mechanism of action of Jintiange capsules(金天格胶囊)in regulating synovial mesenchymal stem cells exosomal miRNA and articular chondrocytes mRNA for the treatment of osteoarthritis

OBJECTIVE: To corroborate the efficacy of Jintiange capsules(JTGs)( 金天格胶囊) in the treatment of osteoarthritis(OA) by exploring the potential mechanism of action of synovial mesenchymal stem cell exosomes(SMSC-Exos) and articular chondrocytes(ACs) through transcriptome sequencing(RNA-seq). METHODS: Type Ⅱ collagenase was used to induce OA in rats. The efficacy of JTGs was confirmed by macroscopic observation of articular cartilage, micro-CT observation, and safranin fast green staining. After SMSC-Exos and ACs were qualified, RNA-seq was used to screen differentially expressed mi RNAs and m RNAs. The target genes of differentially expressed mi RNAs in Synovial mesenchymal stem cells(SMSCs) were predicted based on the multi Mi R R package. The codifferentially expressed genes of SMSC-Exos and ACs were obtained by venny 2.1.0. The mi RNA-m RNA regulatory network was constructed by Cytoscape software. Based on the Omic Share platform, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis was performed on the m RNA regulated by key mi RNAs. Expression trend analysis was performed for co-differentially expressed genes. Correlation analysis was performed on micro-CT efficacy indicators, co-differentially expressed genes mRNA and miRNA. RESULTS: The efficacy of each administration group of JTGs was significant compared with the model group. SMSC-Exos and ACs were identified by their characteristics. The expression of rno-mi R-23a-3p, rnomi R-342-3p, rno-miR-146b-5p, rno-miR-501-3p, rnomiR-214-3p was down-regulated in OA pathological state, and the expression of rno-mi R-222-3p, rno-mi R-30e-3p, rno-mi R-676, and rno-miR-192-5p expression was upregulated, and the expression of all these mi RNAs was reversed after the intervention with JTGs containing serum. The co-differentially expressed genes were enriched in the interleukin 17 signaling pathway, tumor necrosis factor signaling pathway, transforming growth factor-β signaling pathway, etc. The expression trends of Ccl7, Akap12, Grem2, Egln3, Arhgdib, Ccl20, Mmp12, Pla2g2a, and Nr4a1 were significant. There was a correlation between micro-CT pharmacodynamic index, m RNA, and mi RNA. CONCLUSION: JTGs can improve the degeneration of joint cartilage and achieve the purpose of cartilage protection, which can be used for the treatment of OA. SMSCs-related mi RNA expression profiles were significantly altered after the intervention with JTGs containing serum. The 9 co-differentially expressed genes may be the key targets for the efficacy of JTGs in the treatment of OA rats, which can be used for subsequent validation.